The Multiple Myeloma Content Hub Channel
Is Multiple Myeloma Curable? Rafael Fonseca, MD | Mayo Clinic
Multiple Myeloma Content Hub
Rafael Fonseca, MD, discusses the evolving landscape of multiple myeloma treatment. While traditionally deemed incurable, Dr. Fonseca highlights a growing fraction of patients achieving sustained, durable, and potentially…
Mayo Clinic Minute – Advances in Multiple Myeloma Treatment
Multiple Myeloma Content Hub
Multiple Myeloma is a cancer that affects plasma cells in bone marrow. Abnormal plasma cells produce harmful proteins, leading to anemia, bone pain, frequent infections, and kidney failure.…
Recent Videos in Multiple Myeloma Content Hub Page 3
Immunotherapy for Multiple Myeloma
Multiple Myeloma Content Hub
Joseph Mikhael, MD, of @TGen, @cityofhope discusses #immunotherapy for #multiplemyeloma.
Managing Bone Disease in Patients With Multiple Myeloma
Multiple Myeloma Content Hub
@andrew02114, of @MGHCancerCenter and @harvardmed, discusses the management of #bonedisease in patients with #multiplemyeloma.
Announcing the Launch of the Multiple Myeloma Content Hub
Multiple Myeloma Content Hub
Michael Banks, MD, announces the launch of the Multiple Myeloma Content Hub on The Doctor’s Channel. Check back soon for interviews with thought leaders in the space, case…
Dr Raj Chakraborty Discusses Clinical Trial Results for Patients With Newly Diagnosed Multiple Myeloma
Multiple Myeloma Content Hub
Raj Chakraborty, MD, assistant professor of medicine at Columbia University Irving Medical Center, discusses promising results from current clinical trials for newly diagnosed multiple myeloma. The GRIFFIN trial…
Recent Data on Drug Conjugates in Multiple Myeloma
Multiple Myeloma Content Hub
In an interview conducted during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020, Saad Usmani, MD, MBBS, MBA, of the Levine Cancer Institute in…
Dr Luciano Costa Discusses Highlights on Bispecific T-Cell Engagers in Multiple Myeloma From ASH 2020
Multiple Myeloma Content Hub
In an interview recorded during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020, Luciano Costa, MD, PhD, of UAB School of Medicine, Birmingham, AL,…
Early Treatment May Be Beneficial for Patients With High-Risk Smoldering Myeloma
Multiple Myeloma Content Hub
Brian G. M. Durie, MD, chairman of the board of the International Myeloma Foundation, discusses whether patients with borderline high-risk smoldering myeloma should begin treatment early. Some treatments…
Genetic Changes in Smoldering Multiple Myeloma May Be Used to Guide Early Treatment
Multiple Myeloma Content Hub
In a sequencing study of 82 patients with smoldering multiple myeloma, there were fewer NRAS and FAM46C mutations and with fewer adverse translocations – del(1p), del(14q), del(16q), and…
Autologous Stem Cell Transplant Can Increase Development of Second Primary Malignancies in Multiple Myeloma
Multiple Myeloma Content Hub
In a study of 16,331 patients in the California Cancer Registry, 5.7% developed a second primary malignancy more than 1 year after diagnosis. The 10-year cumulative incidence of…
Role of MYC as Driver of PARP1-Mediated Repair and Potential Biomarker of PARPness
Multiple Myeloma Content Hub
In a study designed to investigate the biological relevance of PARP1 in multiple myeloma (MM), data revealed a significant correlation between increased PARP1 mRNA expression and poor prognosis…